Ashkan Shoamanesh Shares OCEANIC-STROKE Trial’s Successful Endpoints
Ashkan Shoamanesh, Associate Professor of Medicine (Neurology), Marta and Owen Boris Chair in Stroke Research and Care at McMaster University, shared on LinkedIn:
”We are absolutely thrilled to share that the OCEANIC-STROKE trial has successfully met its primary efficacy and safety endpoints.
These landmark findings validate our ability to uncouple pathological thrombus formation from hemostasis—a breakthrough that has the potential to have far more reaching impact in the medical care of patients with cardiovascular disease.
Asundexian now emerges as an established treatment option addressing a major unmet need among the approximately 5 million people worldwide who experience a new non-cardioembolic ischemic stroke each year.
We are profoundly grateful for our partnership with Bayer and for the invaluable contributions of our global network of investigators and study teams whose dedication made OCEANIC-STROKE possible.”
Read the full article here.
Stay updated with Hemostasis Today.
-
Apr 9, 2026, 20:33Pat Garcia-Gonzalez: On World Health Day, I’m thinking about what ‘health’ really means.
-
Apr 9, 2026, 19:13Jan Sloves: Patterns and Pitfalls Influencing Treatment of Small Saphenous Vein Reflux
-
Apr 9, 2026, 18:38Jecko Thachil: Why D-dimers are Useful Tests for the Exclusion of Thromboembolism and the Diagnosis of DIC
-
Apr 9, 2026, 18:21New Clinical Practice Guideline on Anticoagulant Prophylaxis in Pediatric Patients at Risk of VTE – ISTH
-
Apr 9, 2026, 16:40We Are Incredibly Grateful to Our Volunteers – Hemophilia of Georgia
-
Apr 9, 2026, 15:10Christoffer Gebhardt: Can Anticoagulation Improve Outcomes in Melanoma Therapy?
-
Apr 9, 2026, 15:09National Institutes of Health Addresses VTE Research Funding Gap – JTH
-
Apr 9, 2026, 15:08Alice Assinger: Recruiting PhD Students for NET-IT Doctoral Program in Vienna
-
Apr 9, 2026, 15:07Hannah Cohen: A Novel Approach to Post-Stroke Gait Rehabilitation